BioLife Solutions Stock Forecast, Price & News

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for BioLife Solutions in the last year. There are currently 6 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" BioLife Solutions stock.
View analyst ratings for BioLife Solutions or view top-rated stocks.

6 brokers have issued 12 month target prices for BioLife Solutions' shares. Their BLFS stock forecasts range from $30.00 to $65.00. On average, they anticipate BioLife Solutions' stock price to reach $42.17 in the next year. This suggests a possible upside of 188.0% from the stock's current price.
View analysts' price targets for BioLife Solutions or view top-rated stocks among Wall Street analysts.

BioLife Solutions' stock was trading at $37.27 at the beginning of the year. Since then, BLFS shares have decreased by 60.7% and is now trading at $14.64.
View the best growth stocks for 2022 here.

BioLife Solutions is scheduled to release its next quarterly earnings announcement on Thursday, August 11th 2022.
View our earnings forecast for BioLife Solutions.

BioLife Solutions, Inc. (NASDAQ:BLFS) posted its quarterly earnings results on Monday, May, 9th. The medical equipment provider reported ($0.19) EPS for the quarter, missing the consensus estimate of ($0.13) by $0.06. The medical equipment provider earned $36.22 million during the quarter, compared to the consensus estimate of $37.87 million. BioLife Solutions had a negative net margin of 10.35% and a negative trailing twelve-month return on equity of 6.24%. During the same quarter in the previous year, the company earned $0.01 EPS.
View BioLife Solutions' earnings history.

BioLife Solutions issued an update on its FY 2022 earnings guidance on Monday, June, 6th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $159.50 million-$171.00 million, compared to the consensus revenue estimate of $165.38 million.

5 employees have rated BioLife Solutions CEO Mike Rice on Glassdoor.com. Mike Rice has an approval rating of 100% among BioLife Solutions' employees. This puts Mike Rice in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Some companies that are related to BioLife Solutions include InMode (INMD), Natus Medical (NTUS), TransMedics Group (TMDX), Outset Medical (OM), Cutera (CUTR), ViewRay (VRAY), AxoGen (AXGN), Zynex (ZYXI), Edap Tms (EDAP), Semler Scientific (SMLR), Hyperfine (HYPR), Stereotaxis (STXS), FONAR (FONR), Electromed (ELMD) and Electromed (ELMD).
View all of BLFS's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other BioLife Solutions investors own include (CGC), Micron Technology (MU), AbbVie (ABBV), Cara Therapeutics (CARA), Gilead Sciences (GILD), Pfizer (PFE), Rigel Pharmaceuticals (RIGL), Sorrento Therapeutics (SRNE), Twilio (TWLO) and Verastem (VSTM).

BioLife Solutions trades on the NASDAQ under the ticker symbol "BLFS."

Shares of BLFS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of BLFS stock can currently be purchased for approximately $14.64.

BioLife Solutions (NASDAQ:BLFS) has a market capitalization of $620.88 million and generates $119.16 million in revenue each year. The medical equipment provider earns $-7.64 million in net income (profit) each year or ($0.350010) on an earnings per share basis.

BioLife Solutions employs 432 workers across the globe.

BioLife Solutions' mailing address is 3303 MONTE VILLA PARKWAY SUITE 310, BOTHELL WA, 98021. The official website for BioLife Solutions is www.biolifesolutions.com. The medical equipment provider can be reached via phone at (425) 402-1400, via email at rdegreef@biolifesolutions.com, or via fax at 425-402-1433.